This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

This study has been completed.
Information provided by (Responsible Party):
LEO Pharma Identifier:
First received: June 9, 2010
Last updated: November 1, 2013
Last verified: November 2013
The study will investigate the impact of reduced renal function on the pharmacokinetic and pharmacodynamic profile of LEO 27847. Volunteers with different degrees of renal impairment will be administered one dose of the investigational drug and then followed until investigational drug is eliminated from the body.

Condition Intervention Phase
Renal Impairment Drug: LEO 27847 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Further study details as provided by LEO Pharma:

Primary Outcome Measures:
  • PK parameters [ Time Frame: 1 week ]
    (AUC, Cmax)in each group of renal impairment

Secondary Outcome Measures:
  • PD parameters [ Time Frame: 1 week ]
    (Calcium, phosphate, PTH), Vitamin D in each group of renal impairment

Enrollment: 25
Study Start Date: May 2010
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LEO 27847 Drug: LEO 27847
2 mL (0.1 mg) dose of oral solution


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Main Inclusion Criteria:

  • Male and/or non-childbearing potential female, 18 years of age and older, healthy or with stable renal impairment (deemed stable by the referring physician for at least the last 4 weeks and not expected to change significantly during the next 3 months)
  • BMI ≥18.0 and ≤ 42 kg/m2
  • Patients with stable concomitant medical conditions
  • Healthy subjects or patients with a creatinine clearance (at the time of screening) estimated using the formula of Cockcroft and Gault within the range of:

    • ≥ 50 to ≤ 80 mL/min (Mild Group: 8 subjects),
    • ≥ 30 to < 50 mL/min (Moderate Group: 8 subjects),
    • < 30 mL/min (Severe Group: 8 subjects).

Main Exclusion Criteria:

  • Patients with renal transplants or currently on haemodialysis or peritoneal dialysis
  • Clinically significant illness or surgery within 4 weeks prior to dosing
  • Clinically significant ECG abnormalities or vital sign abnormalities at screening
  • History of stroke, cerebrovascular disorder, coronary angioplasty and coronary bypass graft
  • Clinically significant history or presence of any gastrointestinal pathology
  • Use of medications other than their stable medications within 14 days prior to administration of investigational product or over-the-counter products within 7 days prior to administration of investigational product, except for:

    • multivitamins or vitamin D taken on a regular basis
    • topical products without systemic absorption
  • Hemoglobin ≤ 90 g/L
  • Serum total calcium (adjusted for albumin) level < 2.25 mmol/L
  • Clinically significant history of congestive heart failure, cardiac dysfunction or liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01141179

Canada, Ontario
Toronto, Ontario, Canada, M2P 1N6
Sponsors and Collaborators
LEO Pharma
Principal Investigator: Richard Larouche, MD Anapharm
  More Information

Responsible Party: LEO Pharma Identifier: NCT01141179     History of Changes
Other Study ID Numbers: LEO 27847-S03
Study First Received: June 9, 2010
Last Updated: November 1, 2013

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases processed this record on June 26, 2017